Rebamipid Global Buyers List: A Complete Guide to Importers, API Purchasers, and Trade Opportunities
Rebamipide is a gastroprotective agent widely used in the treatment of gastritis, gastric ulcers, and mucosal damage induced by non-steroidal anti-inflammatory drugs (NSAIDs). As demand for this API continues to grow across Asia, Europe, and emerging markets, pharmaceutical suppliers and exporters need accurate, up-to-date information about who is buying Rebamipide globally. This guide provides a structured overview of the Rebamipid global buyers list, covering key importing countries, active purchasers, and practical strategies for connecting with verified buyers.
Understanding the Rebamipide Market Landscape
Rebamipide is a white crystalline powder that functions by stimulating gastric mucus secretion, enhancing the mucosal barrier, and scavenging free radicals. The global Rebamipide drugs market was valued at approximately US420millionandisprojectedtoreachUS 491 million by 2031, growing at a compound annual growth rate (CAGR) of 2.3%. China alone accounts for more than 45% of the global market share, with a historical compound annual growth rate of 6.8%—well above the global average.
This sustained growth is driven by several factors, including the rising prevalence of gastrointestinal disorders, increasing awareness of gastric mucosal protection, and the expanding use of Rebamipide in combination therapies. For exporters and API manufacturers, understanding the geographical distribution of demand is the first step toward building a successful buyer list.
Key Countries Importing Rebamipide
Trade data reveals a concentrated but dynamic import landscape. According to verified B2B transaction records, Vietnam leads global imports with a 35.38% share, while China dominates exports with a 51.81% share. Other significant importing nations include:
- Japan – A mature market with consistent demand for both API and finished dosage forms. Japan imports Rebamipide film-coated tablets from India, with major purchasers including ME Pharma Co., Ltd..
- Russia – Identified as a leading import country for Rebamipide API.
- Pakistan – Another key import market for Rebamipide API.
- South Korea – A significant market where Rebamipide is sold under brand names such as Rebagen and Rebagit.
- Uzbekistan – Emerging as a buyer of finished Rebamipide tablets, with imports from Indian manufacturers.
These markets represent the highest-priority targets for suppliers seeking to expand their Rebamipide buyer network.
Major Rebamipide Buyers and Importers
The following organizations have been identified through trade data and market research as active purchasers or importers of Rebamipide:
Verified Importers and Purchasers
| Buyer/Importer | Country | Product Type |
|---|---|---|
| ME Pharma Co., Ltd. | Japan | Rebamipide film-coated tablets |
| Kaufmann Pharma Inc. | — | Mucopro 100mg tablets (Rebamipide 100mg) |
| CPC1 Central Pharmaceutical JSC | Vietnam | Rebamipide 100mg finished products |
| FE Advance Pharmaceutical Business | Uzbekistan | Mucogen Rebamipide tablets 100mg |
| Navis Vietnam Manufacturing Co., Ltd. | Vietnam | Rebamipide API and finished forms |
| Nippon Chemiphar Vietnam Co., Ltd. | Vietnam | Rebamipide finished products |
ME Pharma Co., Ltd. in Japan has been particularly active, importing Rebamipide film-coated tablets from Medreich Ltd. in India through the Yokohama port. Kaufmann Pharma Inc. has also been recorded as a purchaser of Mucopro 100mg tablets containing Rebamipide.
Rebamipide API Distributors and Buyers
Pharmaoffer’s transaction tracking system has recorded 472 verified B2B transactions for Rebamipide, involving 89 exporters and 140 importers. The top importing companies identified in trade records include:
- Clearsynth Labs Limited
- Nihon Pharmaceutical Industry Co., Ltd.
- Navis Vietnam Manufacturing Co., Ltd.
- Nippon Chemiphar Vietnam Co., Ltd.
These distributors and manufacturers represent reliable entry points for suppliers looking to establish long-term relationships in the Rebamipide trade.
Rebamipide API Buyers by Region
Asia-Pacific
The Asia-Pacific region is the epicenter of Rebamipide demand. China, Japan, South Korea, and Vietnam are the primary markets, with Vietnam showing particularly strong import activity. Chinese manufacturers such as Jiangxi Synergy Pharmaceutical Co., Ltd. have been recorded as exporters to Vietnam.
Europe
European buyers are increasingly seeking Rebamipide API for generic drug development. Companies like Summit Pharmaceuticals Europe Srl and Aurore Life Sciences have been identified as key players in the European Rebamipide supply chain.
North America
While North America represents a smaller share of the global Rebamipide market, pharmaceutical manufacturers in the region are exploring Rebamipide for gastrointestinal applications. Major global companies including Teva, Viatris, and Amneal Pharmaceuticals have Rebamipide products in their portfolios.
Middle East and Africa
The Middle East and Africa represent emerging markets for Rebamipide, with increasing imports of finished dosage forms. Uzbekistan has been identified as an active purchaser of Rebamipide tablets.
Major Rebamipide Manufacturers and Suppliers
Understanding the supply side is equally important for buyers and sellers alike. The leading Rebamipide manufacturers globally include:
- Otsuka Pharmaceutical – The original patent holder and a dominant force in the Rebamipide market.
- Anlon Healthcare Pvt Ltd
- Suzhou Tianma Pharmaceutical Group
- Menovo
- Macleods Pharma
- Saurav Chemicals
- SAMOH Pharm
- Kyung Dong Pharm
- Strides Pharma Science
- Dong Wha Pharm
- Cheer Fine Pharmaceutical
Other notable manufacturers include Chongqing Shenghuaxi Pharmaceutical, Guangzhou Tosun Pharmaceutical, Zhejiang Liaoyuan Pharmaceutical, and Jiangxi Synergy Pharmaceutical. These companies form the backbone of the global Rebamipide supply chain and are often the primary sources for buyers seeking API or finished dosage forms.
How to Build a Verified Rebamipide Buyers List
Creating an effective Rebamipid global buyers list requires a systematic approach that combines trade data analysis, regulatory verification, and direct outreach.
Step 1: Leverage Trade Intelligence Platforms
Platforms such as Pharmaoffer, Volza, and 52wmb provide verified B2B transaction data for Rebamipide. Pharmaoffer alone tracks 472 transactions with detailed exporter and importer information. These platforms allow you to filter buyers by country, transaction volume, and product type.
Step 2: Monitor Customs and Import Records
Customs data from key importing countries—particularly Japan, Vietnam, Russia, and Pakistan—can reveal active buyers. For example, Japanese import records show regular shipments of Rebamipide tablets from Indian manufacturers to ME Pharma Co., Ltd.. Monitoring HS Code 30049039 (which covers Rebamipide formulations) can help identify new buyers entering the market.
Step 3: Verify Buyer Credibility
Before adding a buyer to your list, verify their regulatory status. Check whether the buyer holds the necessary pharmaceutical import licenses and whether they have a history of compliant trade. GMP certification is a strong indicator of a serious buyer.
Step 4: Attend Industry Events
Pharmaceutical trade shows and API-focused conferences in Asia, Europe, and the Middle East provide valuable opportunities to meet Rebamipide buyers face-to-face. These events often attract procurement managers from hospitals, pharmaceutical manufacturers, and wholesale distributors.
Step 5: Use Direct Outreach
Once you have identified potential buyers, reach out with a clear value proposition. Highlight your manufacturing capabilities, regulatory compliance, and pricing competitiveness. Personalized outreach is far more effective than mass email campaigns.
Regulatory Considerations for Rebamipide Trade
Rebamipide is regulated as a pharmaceutical product in most jurisdictions, which means buyers and sellers must comply with strict regulatory requirements. Key considerations include:
- GMP Certification – Buyers typically require suppliers to hold valid GMP certification for Rebamipide API and finished products.
- Import Licenses – Buyers in regulated markets must hold appropriate import licenses for pharmaceutical products.
- Product Registration – In many countries, Rebamipide products must be registered with the national drug regulatory authority before they can be legally imported and sold.
- Documentation – Certificates of Analysis (CoA), Material Safety Data Sheets (MSDS), and stability data are commonly required for Rebamipide shipments.
Understanding these requirements is essential for both buyers and sellers to ensure smooth transactions and avoid regulatory delays.
Rebamipide Trade Data: Key Insights
Recent trade data provides valuable insights into the Rebamipide market:
- Export Leader: China, with a 51.81% share of global exports.
- Import Leader: Vietnam, with a 35.38% share of global imports.
- Market Size: The global Rebamipide drugs market was valued at US420millionandisprojectedtoreachUS 491 million by 2031.
- China’s Market Share: More than 45% of the global market.
- Historical Growth Rate: 6.8% CAGR in China over the past three years, exceeding the global average.
These figures underscore the importance of Asia as both a production hub and a consumption center for Rebamipide. Suppliers targeting global buyers should prioritize relationships with importers in Vietnam, Japan, and other high-demand markets.
Frequently Asked Questions (FAQ)
What is Rebamipide used for?
Rebamipide is a gastroprotective agent used to treat gastritis, gastric ulcers, and mucosal damage caused by NSAIDs. It works by stimulating gastric mucus secretion and enhancing the mucosal barrier.
Which countries are the largest importers of Rebamipide?
Vietnam is the largest importer of Rebamipide API, followed by Japan, Russia, and Pakistan.
Who are the major Rebamipide manufacturers?
Major manufacturers include Otsuka Pharmaceutical, Anlon Healthcare Pvt Ltd, Suzhou Tianma Pharmaceutical Group, Menovo, Macleods Pharma, and several others.
How can I find verified Rebamipide buyers?
Use trade intelligence platforms such as Pharmaoffer, Volza, and 52wmb, monitor customs records, and verify buyer credentials through regulatory databases.
What is the market outlook for Rebamipide?
The global Rebamipide market is projected to grow at a CAGR of 2.3%, reaching US$ 491 million by 2031.
What regulatory requirements apply to Rebamipide trade?
Buyers and sellers must comply with GMP certification, import licensing, product registration, and documentation requirements specific to each country.
CÔNG TY TNHH NIPPON CHEMIPHAR VIỆT NAM
CÔNG TY TNHH DKSH PHARMA VIỆT NAM
PT NARDA TITA
MEDREICH LIMITED
AO PRO MED CS
CÔNG TY TNHH SẢN XUẤT NAVIS VIỆT NAM
PT INTERBAT
CÔNG TY CỔ PHẦN DƯỢC PHẨM ĐẠT VI PHÚ
JUSTRIGHT HEALTHCARE INC
CÔNG TY CỔ PHẦN XUẤT NHẬP KHẨU Y TẾ THÁI AN
АТ КИЇВМЕДПРЕПАРАТ 01032 УКРАЇНА М КИЇВ ВУЛ САКСАГАНСЬКОГО 139
CÔNG TY CỔ PHẦN HÓA CHẤT Á CHÂU
CÔNG TY CỔ PHẦN THƯƠNG MẠI DƯỢC PHẨM QUỐC TẾ PHÚC ĐAN
CÔNG TY TNHH LIÊN DOANH STELLAPHARM CHI NHÁNH 1
CÔNG TY TNHH VẬT TƯ KHOA HỌC CÔNG NGHỆ T T
INTELIGENCIA EN SOLUCIONES REGULATORIAS SA DE CV
KAIZEN PHARMACEUTICALS PVT LTD
CÔNG TY CỔ PHẦN KOREA UNITED PHARM INT L
CÔNG TY TNHH HÓA DƯỢC TOÀN PHÚC
CÔNG TY TNHH THƯƠNG MẠI DỊCH VỤ HÓA DƯỢC VIỆT
ETERCON PHARMA
KAUFMANN PHARMA INC
MCOLSON RESEARCH LABORATORIES PRIVATE LIMITED
ONE PHARMA MARKETING INC
PRIMA MEDIKA LABORATORIES
PT PRATAPA NIRMALA
ИП ООО ADVANCE PHARMACEUTICAL BUSINESS
API INTERNATIONAL
CÔNG TY CỔ PHẦN DƯỢC THIẾT BỊ Y TẾ ĐÀ NẴNG
CÔNG TY CỔ PHẦN TM XNK GALAXY VIỆT NAM
CÔNG TY TNHH THƯƠNG MẠI H B C
LLC PROMED CS
MCOLSON RESEARCH LABORATORIES PVT LTD
OTSUKA PHILIPPINES PHARMACEUTICAL
PHARMARAW BANGLADESH PRB
PT MEPROFARM
PT MERCK CHEMICALS AND LIFE SCIENCES
ООО HURSHIDA ENTER DELUX
CHEMKEY BANGLADESH
CÔNG TY CỔ PHẦN DƯỢC HẬU GIANG
CÔNG TY CỔ PHẦN DƯỢC PHẨM SAVI
CÔNG TY CỔ PHẦN DƯỢC ĐỒNG NAI
CÔNG TY CỔ PHẦN TRAPHACO
DR REDDY S LABORATORIES LTD
HORIZON HEALTHCARE PRIVATE LIMITED MANUFACTURING UNIT 02
KARUNIA JASINDO
MAX VISION SRL
PT LAPI LABORATORIES
TOKYO CHEMICAL INDUSTRY INDIA PRIVATE LIMITED
BEXIMCO PHARMACEUTICALS LIMITED
BIOBIZ INTERNATIONAL
CARER PHARMACEUTICALS INDUSTRIES
CÔNG TY CỔ PHẦN DƯỢC ENLIE
CÔNG TY CỔ PHẦN DƯỢC PHẨM CPC1 HÀ NỘI
CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG CPC1 CHI NHÁNH THÀNH PHỐ HỒ CHÍ MINH
CÔNG TY CỔ PHẦN KHOA HỌC CÔNG NGHỆ T T
CÔNG TY TNHH DOOSAN ENERBILITY VIỆT NAM
CÔNG TY TNHH KHOA HỌC NNC
CÔNG TY TNHH MTV NOVALAB
CÔNG TY TNHH THƯƠNG MẠI DƯỢC PHẨM HOÀNG TRÂN
ETERCON PHARMA PT
GENECHT RESEARCH PRIVATE LIMITED
HIRANIS PHARMACEUTICALS PVT LIMITED
HORIZON HEALTHCARE PVT LTD
INCEPTA PHARMACEUTICALS LIMITED
JINAY PHARMACEUTICALS PRIVATE LIMITED
LAMBDA THERAPEUTIC RESEARCH LIMITED
LOTUS LABS PRIVATE LIMITED
NOVAMED PHARMACEUTICALS PVT LIMITED
NOVAMED PHARMACEUTICALS PVT LTD
PT IFARS PHARMACEUTICAL LABORATORIES
PT OTSUKA INDONESIA
SAMI PHARMACEUTICALS PVT LIMITED
WORLD MEDICINE ILAC SANAYI VE TICARET ANONIM SIRKETI
АО АЛИУМ
ТОВ МАКЛЕОДС ФАРМАСЬЮТІКАЛЗ ЛІМІТЕД 02092 М КИЇВ ВУЛ ОЛЕКСИ ДОВБУША 37
ARISTOPHARMA LTD CHANGE FROM
BTL BIOTECHNO LABS PRIVATE LIMITED
CARGOMIND CZECH REPUBLIC S R O
CARGOMIND GERMANY GMBH
CHI NHÁNH CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG CODUPHA HÀ NỘI
CÁ NHÂN TỔ CHỨC KHÔNG CÓ MÃ SỐ THUẾ
CÔNG TY CP DƯỢC PHẨM IMEXPHARM
CÔNG TY CỔ PHẦN DƯỢC PHẨM ASIA
CÔNG TY CỔ PHẦN DƯỢC PHẨM SAO KIM
CÔNG TY CỔ PHẦN DƯỢC PHẨM SOHA VIMEX
CÔNG TY CỔ PHẦN DƯỢC PHẨM TV PHARM
CÔNG TY CỔ PHẦN DƯỢC PHẨM VIỆT NGA
CÔNG TY CỔ PHẦN DƯỢC PHẨM WEALPHAR
CÔNG TY CỔ PHẦN HOÁ DƯỢC HIỆP LỰC
CÔNG TY CỔ PHẦN HÓA CHẤT GLOBAL HUB
CÔNG TY LIÊN DOANH MEYER BPC
CÔNG TY TNHH SAMIL PHARMACEUTICAL
DELTA PHARMA LIMITED
EFFORT PHARMACEUTICALS PRIVATE LIMITED
EFFORT PHARMACEUTICALS PVT LTD
ELCON DRUGS AND FORMULATIONS LIMITED
ELECTROCRAFTS
GERRY S INTERNATIONAL PRIVATE LIMITED
GRAND CORPORATION PVT LTD
HIRANIS PHARMACEUTICALS PVT LTD
HORIZON HEALTH CARE PVT LTD
INTERFACE
KUSUM HEALTHCARE PRIVATE LIMITED
LLC NSD GROUP TIB
M S HELIX PHARMA PRIVATE LIMITED
M S PACIFIC PHARMACEUTICALS LTD
M S WNSFIELD PHARMACEUTICLS
MCOLSON RESEARCH LABORATORIES
MEDIZAN LABORATORIES PVT LTD
NOVELL PHARMACEUTICAL LABORATORIES
OTSUKA INDONESIA
PACIFIC PHARMACEUTICALS LTD
PHARMEDIC LABORATORIES PVT LTD
PRIMA MEDIKA LABORATORIES PT
PT DEXA MEDICA
REGAL PHARMACEUTICAL
REGAL PHARMACEUTICALS
RITEMED PHILS INC
SIDUS SOCIEDAD ANONIMA
TECHSTREAM CORPORATION LTD
THE CHEMICALS
WNSFEILD PHARMACEUTICALS
ИП ADVANCE PHARMACEUTICAL BUSINESS
КОРПОРАЦІЯ АРТЕРІУМ 01032 М КИЇВ ВУЛ САКСАГАНСЬКOГO 139 УКРАЇНА
КОРПОРАЦІЯ АРТЕРІУМ 01032 М КИЇВ ВУЛ САКСАГАНСЬКОГО 139 УКРАЇНА
КОРПОРАЦІЯ АРТЕРІУМ М КИЇВ ВУЛ САКСАГАНСЬКОГО 139
ТОО DPB NEW BRANDS
ЧП NSD GROUP TIB
Conclusion
The Rebamipid global buyers list is a dynamic and growing resource for pharmaceutical suppliers, exporters, and manufacturers. With Vietnam leading imports, China dominating exports, and markets across Asia, Europe, and the Middle East showing sustained demand, the opportunities for Rebamipide trade are substantial. By leveraging trade intelligence platforms, monitoring customs data, and verifying buyer credentials, suppliers can build a robust network of verified buyers and capitalize on the growing global demand for this essential gastroprotective agent.
For the most accurate and up-to-date buyer information, combining multiple data sources—including trade databases, regulatory filings, and industry events—remains the most effective strategy.


